文献速递肝病

COVID-19大流行对美国肝病相关死亡率的影响

Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States.
PubMed 文献 · J Hepatol · 2022-08-18

研究利用美国CDC WONDER平台2010-2021年死亡数据,分析COVID-19大流行对肝病相关死亡率的影响。结果显示,酒精相关性肝病(ALD)和非酒精性脂肪性肝病(NAFLD)的年龄标化死亡率在2020-2021年显著上升,远超基于2010-2019年趋势的预测值,且在年轻人、非西班牙裔白人及阿拉斯加印第安人/原住民中差异最大。

要点

  • 2020-2021年ALD的年龄标化死亡率(每10万人)观察值高于预测值:2020年15.67 vs 13.04,2021年17.42 vs 13.41。
  • NAFLD的年龄标化死亡率在大流行期间亦上升,年百分比变化(APC)为14.5%,而乙型和丙型肝炎死亡率下降。
  • ALD死亡率上升在25-44岁年龄组最为严重(APC 34.6%),高于45-64岁(13.7%)和≥65岁(12.6%)组。

核心结论

  • COVID-19大流行期间,ALD和NAFLD的年龄标化死亡率以惊人速度上升,在年轻人、非西班牙裔白人及阿拉斯加印第安人/原住民人群中差异最大。
  • 作者认为,在大流行持续及恢复阶段,应优先坚持对慢性肝病患者的定期监测和照护,并提高患者、照护者、医疗系统和公共卫生政策制定者的意识。

研究设计与样本

  • 研究利用美国疾病控制与预防中心(CDC)WONDER平台的全国生命统计系统数据,通过ICD-10编码识别肝病相关死亡。
  • 研究纳入2010-2021年间626,090例慢性肝病相关死亡,采用Joinpoint回归和预测模型分析,基于2010-2019年趋势评估2020-2021年观察死亡率与预测死亡率。

主要发现

  • 2010-2019年至2020-2021年间,ALD的年龄标化死亡率年百分比变化(APC)从3.5%升至17.6%(p<0.01),观察值高于预测值:2020年15.67 vs 13.04,2021年17.42 vs 13.41(每10万人)。
  • NAFLD的年龄标化死亡率在大流行期间上升(APC 14.5%),而乙型和丙型肝炎死亡率下降。
  • ALD死亡率上升在非西班牙裔白人、黑人及阿拉斯加印第安人/原住民中最为显著(APC分别为11.7%、10.8%、18.0%,均p<0.05),NAFLD有相似但较不严重的发现,而非西班牙裔亚裔的死亡率在2010-2021年间保持稳定(APC 4.9%)。
  • ALD死亡率上升在25-44岁年龄组尤为严重(APC 34.6%,对比45-64岁13.7%和≥65岁12.6%,均p<0.01),且各年龄组均高于COVID-19前水平(均p<0.01)。

临床怎么用

  • 作者认为,在大流行持续及恢复阶段,应优先坚持对慢性肝病患者的定期监测和照护,并提高患者、照护者、医疗系统和公共卫生政策制定者的意识。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The pandemic has resulted in an increase of deaths not directly related to COVID-19 infection. We aimed to use a national death dataset to determine the impact of the pandemic on people with liver disease in the USA, focusing on alcohol-associated liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD). METHODS: Using data from the National Vital Statistic System from the Center for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) platform and ICD-10 codes, we identified deaths associated with liver disease. We evaluated observed vs. predicted mortality for 2020-2021 based on trends from 2010-2019 with joinpoint and prediction modelling analysis. RESULTS: Among 626,090 chronic liver disease-related deaths between 2010 and 2021, Age-standardised mortality rates (ASMRs) for ALD dramatically increased between 2010-2019 and 2020-2021 (annual percentage change [APC] 3.5% to 17.6%, p <0.01), leading to a higher observed ASMR (per 100,000 persons) than predicted for 2020 (15.67 vs. 13.04) and 2021 (17.42 vs. 13.41). ASMR for NAFLD also increased during the pandemic (APC: 14.5%), whereas the rates for hepatitis B and C decreased. Notably, the ASMR rise for ALD was most pronounced in non-Hispanic Whites, Blacks, and Alaska Indians/Native Americans (APC: 11.7%, 10.8%, 18.0%, all p <0.05), with similar but less critical findings for NAFLD, whereas rates were steady for non-Hispanic Asians throughout 2010-2021 (APC: 4.9%). The ASMR rise for ALD was particularly severe for the 25-44 age group (APC: 34.6%, vs. 13.7% and 12.6% for 45-64 and ≥65, all p <0.01), which were also all higher than pre-COVID-19 rates (all p <0.01). CONCLUSIONS: ASMRs for ALD and NAFLD increased at an alarming rate during the COVID-19 pandemic with the largest disparities among the young, non-Hispanic White, and Alaska Indian/Native American populations. IMPACT AND IMPLICATIONS: The pandemic has led to an increase of deaths directly and indirectly related to SARS-CoV-2 infection. As shown in this study, age-standardised mortality rates for alcohol-associated liver disease and non-alcoholic fatty liver disease substantially increased during the COVID-19 pandemic in the USA and far exceeded expected levels predicted from past trends, especially among the young, non-Hispanic White, and Alaska Indian/Native American populations. However, much of this increase was not directly related to COVID-19. Therefore, for the ongoing pandemic as well as its recovery phase, adherence to regular monitoring and care for people with chronic liver disease should be prioritised and awareness should be raised among patients, care providers, healthcare systems, and public health policy makers.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Gao X, Lv F, He X, et al. Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States. J Hepatol. 2022. PMID: 35988691. doi:10.1016/j.jhep.2022.07.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。